iShares Trust. Holdings as of Jun 30, 2026, from Form N-PORT.
Share of net assets at the report date, for the whole fund across all share classes.
| Holding | Weight | Value | Shares or units |
|---|---|---|---|
| JOHNSON & JOHNSONJNJ | 22.44% | $255.48M | 1,005,964 |
| ELI LILLY AND COMPANYLLY | 22.25% | $253.23M | 211,122 |
| BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency SharesCash or money market | 6.24% | $71.06M | 71,038,218 |
| MERCK & CO., INC.MRK | 4.55% | $51.77M | 402,911 |
| BRISTOL-MYERS SQUIBB COMPANYBMY | 4.37% | $49.73M | 862,993 |
| ROYALTY PHARMA PLCRPRX | 4.33% | $49.35M | 880,087 |
| VIATRIS INC.VTRS | 4.22% | $48.05M | 3,025,794 |
| PFIZER INC.PFE | 3.96% | $45.13M | 1,874,313 |
| ZOETIS INC.ZTS | 3.73% | $42.42M | 590,261 |
| JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANYJAZZ | 3.45% | $39.28M | 163,023 |
| ELANCO ANIMAL HEALTH INCORPORATEDELAN | 2.81% | $31.94M | 1,297,692 |
| AXSOME THERAPEUTICS, INC.AXSM | 2.41% | $27.49M | 112,311 |
| CORCEPT THERAPEUTICS INCORPORATEDCORT | 1.90% | $21.58M | 248,243 |
| LIGAND PHARMACEUTICALS INCORPORATEDLGND | 1.45% | $16.46M | 52,070 |
| Definium Therapeutics IncDFTX | 1.39% | $15.81M | 336,035 |
| Liquidia CorpLQDA | 1.28% | $14.55M | 182,536 |
| INDIVIOR PHARMACEUTICALS, INC.INDV | 1.14% | $13.00M | 316,782 |
| Crinetics Pharmaceuticals Inc | 0.90% | $10.25M | 273,936 |
| ORGANON & CO.OGN | 0.81% | $9.25M | 683,028 |
| Edgewise Therapeutics IncEWTX | 0.70% | $7.96M | 195,894 |
| AMNEAL PHARMACEUTICALS, INC.AMRX | 0.68% | $7.76M | 448,079 |
| Enliven Therapeutics IncELVN | 0.63% | $7.18M | 141,435 |
| SUPERNUS PHARMACEUTICALS, INC.SUPN | 0.62% | $7.02M | 150,961 |
| Tarsus Pharmaceuticals IncTARS | 0.57% | $6.47M | 102,786 |
| Veradermics IncMANE | 0.56% | $6.40M | 52,065 |
| Alumis IncALMS | 0.55% | $6.23M | 221,521 |
| NEKTAR THERAPEUTICSNKTR | 0.54% | $6.13M | 87,878 |
| PRESTIGE CONSUMER HEALTHCARE INC.PBH | 0.51% | $5.81M | 122,984 |
| Trevi Therapeutics IncTRVI | 0.50% | $5.72M | 306,511 |
| OCULAR THERAPEUTIX, INC.OCUL | 0.39% | $4.47M | 455,448 |
| INNOVIVA, INC.INVA | 0.36% | $4.14M | 182,305 |
| Amylyx Pharmaceuticals IncAMLX | 0.35% | $3.94M | 219,612 |
| ANI PHARMACEUTICALS, INC.ANIP | 0.34% | $3.92M | 47,404 |
| MBX Biosciences IncMBX | 0.34% | $3.82M | 69,247 |
| HARMONY BIOSCIENCES HOLDINGS, INC.HRMY | 0.33% | $3.78M | 103,804 |
| PERRIGO COMPANY PUBLIC LIMITED COMPANYPRGO | 0.33% | $3.74M | 359,528 |
| HARROW, INC.HROW | 0.32% | $3.66M | 86,214 |
| NUVATION BIO INC.NUVB | 0.32% | $3.60M | 633,601 |
| XERIS BIOPHARMA HOLDINGS, INC.XERS | 0.31% | $3.55M | 448,501 |
| Rapport Therapeutics IncRAPP | 0.27% | $3.11M | 74,520 |
| Collegium Pharmaceutical, Inc.COLL | 0.27% | $3.05M | 84,237 |
| EYEPOINT, INC.EYPT | 0.26% | $2.93M | 204,659 |
| AtaiBeckley Inc | 0.23% | $2.67M | 506,160 |
| PACIRA BIOSCIENCES, INC.PCRX | 0.23% | $2.59M | 102,108 |
| WAVE Life Sciences LtdWVE | 0.20% | $2.29M | 394,231 |
| Maze Therapeutics IncMAZE | 0.19% | $2.18M | 73,160 |
| LB Pharmaceuticals IncLBRX | 0.18% | $2.05M | 63,173 |
| BIOAGE Labs IncBIOA | 0.18% | $2.03M | 82,938 |
| Septerna IncSEPN | 0.18% | $2.00M | 59,605 |
| AMPHASTAR PHARMACEUTICALS, INC.AMPH | 0.16% | $1.79M | 88,493 |
Holdings from the fund's latest Form N-PORT; expense ratio (net of fee waivers) from the risk/return summary of its prospectus; fund type from Form N-CEN. Prices are end-of-day closes adjusted for splits; total return also reinvests distributions.